June 18, 2019

Dr. Thomas Ullman, chief, Gastroenterology, Montefiore, and professor, Medicine, Einstein, discusses how the first biologic therapy approved for inflammatory bowel disease in Canada did not lead to lower rates of hospitalizations or intestinal surgeries for the disorder in Ontario.

Read the Reuters Article